S.M.A.I.O

ALSMA.PA's capital structure shows a debt-to-equity ratio of 0.79, indicating a moderate level of leverage relative to its equity base. The company's liquidity position is characterized by a current ratio of 2.83, suggesting it has sufficient short-term assets to cover its short-term liabilities. However, the company's free cash flow is negative at -2.52 million EUR, which may limit its ability to fund operations or invest in growth without external financing.

In terms of profitability, ALSMA.PA is currently unprofitable, with an operating loss of 2.61 million EUR and a net loss of 2.23 million EUR. The company's return on equity is -37.09%, and its return on assets is -15.8%, both significantly below the industry norms for pharmaceutical companies. These metrics suggest that the company is not generating returns that meet the expectations of its shareholders or asset base.

ALSMA.PA's revenue is concentrated in a single business segment, as no segmental breakdown is provided in the available data. The company's geographic exposure is not explicitly detailed, but its primary operations are likely centered in Europe, given its listing on the Paris stock exchange. This lack of diversification may expose the company to regional economic or regulatory risks.

The company's growth trajectory is uncertain, as it is currently reporting a net loss and negative free cash flow. Analysts have provided a mean price target of 8.30 EUR, with a median of 8.30 EUR, indicating a relatively neutral outlook. The absence of a clear growth strategy or significant revenue expansion in the financial data suggests that the company may need to implement cost-cutting measures or secure additional financing to improve its financial position.

ALSMA.PA faces several risk factors, including its negative net cash position after accounting for total debt. The company's liquidity risk is rated as medium, and its dilution risk is low, suggesting that while it may need to raise capital, it is not currently at high risk of issuing new shares that could dilute existing shareholders. The company has not disclosed any recent events or filings that would indicate significant operational or strategic changes.

Recent events and filings for ALSMA.PA do not show any material developments that would significantly impact its financial position or strategic direction. The company's financial statements and disclosures do not indicate any recent acquisitions, divestitures, or major regulatory changes that would affect its operations or market position.